(Approval lapsed) Chlorpromazine hydrochloride injection, USP 50mg/2mL ampoule (Hikma)

Treatment of acute functional psychosis (e.g. schizophrenia, mania or psychotic depression). Long-term treatment of schizophrenia. Short-term treatment of agitation and severe depression. Severe behavioural disturbances, as can be found in some children with mental retardation or autism, including the treatment of selfinjurious and aggressive behaviour or overactivity. Use of chlorpromazine should be in conjunction with an appropriate nonpharmacological management program and long-term use should only be carried out under the supervision of a physician experienced in the management of psychotic disorders in children. In the management of terminal illness to control nausea and vomiting. Control of intractable hiccough.